Short Interest in Gilead Sciences, Inc. (GILD) Declines By 14.0%

Share on StockTwits

Gilead Sciences, Inc. (NASDAQ:GILD) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 11,548,612 shares, a decrease of 14.0% from the January 15th total of 13,429,498 shares. Currently, 0.9% of the shares of the company are sold short. Based on an average daily volume of 7,327,632 shares, the days-to-cover ratio is presently 1.6 days.

GILD has been the subject of several research analyst reports. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 8th. Raymond James reissued a “buy” rating on shares of Gilead Sciences in a report on Thursday, November 1st. Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, November 1st. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a report on Wednesday, October 31st. Finally, Guggenheim started coverage on shares of Gilead Sciences in a report on Monday, December 17th. They issued a “buy” rating and a $86.00 price target on the stock. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $84.01.

GILD opened at $65.94 on Thursday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.29 and a current ratio of 3.36. Gilead Sciences has a twelve month low of $60.32 and a twelve month high of $82.71. The stock has a market capitalization of $87.28 billion, a PE ratio of 10.72, a PEG ratio of 66.65 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same period in the previous year, the company posted $1.78 EPS. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. Analysts expect that Gilead Sciences will post 6.23 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be issued a $0.63 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $2.52 annualized dividend and a dividend yield of 3.82%. Gilead Sciences’s dividend payout ratio is presently 37.07%.

In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the completion of the transaction, the director now directly owns 2,877,762 shares in the company, valued at approximately $204,896,654.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.16% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of GILD. Sumitomo Mitsui Asset Management Company LTD grew its holdings in shares of Gilead Sciences by 42.2% in the 3rd quarter. Sumitomo Mitsui Asset Management Company LTD now owns 130,139 shares of the biopharmaceutical company’s stock worth $10,048,000 after purchasing an additional 38,633 shares during the last quarter. First Hawaiian Bank bought a new stake in Gilead Sciences during the 3rd quarter worth about $3,429,000. Andra AP fonden grew its holdings in Gilead Sciences by 4.5% during the 3rd quarter. Andra AP fonden now owns 187,000 shares of the biopharmaceutical company’s stock worth $14,438,000 after acquiring an additional 8,100 shares during the last quarter. Raymond James Trust N.A. grew its holdings in Gilead Sciences by 7.7% during the 3rd quarter. Raymond James Trust N.A. now owns 24,469 shares of the biopharmaceutical company’s stock worth $1,889,000 after acquiring an additional 1,746 shares during the last quarter. Finally, DORCHESTER WEALTH MANAGEMENT Co grew its holdings in Gilead Sciences by 21.3% during the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 78,638 shares of the biopharmaceutical company’s stock worth $6,072,000 after acquiring an additional 13,835 shares during the last quarter. 80.03% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Short Interest in Gilead Sciences, Inc. (GILD) Declines By 14.0%” was published by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/2019/02/14/short-interest-in-gilead-sciences-inc-gild-declines-by-14-0/3214533.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: How is an ETF different from a mutual fund?

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.